Market Overview:
The global fibrate drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of obesity and metabolic syndrome, rising geriatric population, and growing demand for combination therapies. Fibrates are used for the treatment of hyperlipidemia, which is a condition characterized by high levels of cholesterol and triglycerides in the blood. They are also used for the prevention of heart disease and stroke. Lofibrate, fenofibrates, fenofibric acids, and gemfibrozil are some of the major types of fibrates available in the market. Hospitals pharmacies accounted for majority share (around 60%) of the global fibrate drugs market in 2017.
Product Definition:
Fibrate drugs are a class of medications used to lower blood cholesterol levels. They work by increasing the breakdown of fats in the body. Fibrate drugs are important for people with high cholesterol levels who cannot take statins or for whom statins are not effective.
Lofibrate:
Lofibrate is a fibrate drug and works by inhibiting the formation of new blood clots. It also prevents the dissolving of existing blood clots. Lofibrate is used in patients with coronary heart disease, peripheral vascular disease, stroke prevention and treatment, rheumatoid heart disease, chronic kidney Disease (CKD), liver diseases or cancer who are at risk of developing blood clots.
Fenofibrates:
Fenofibrates are chemical compounds and have been used as anti-foaming agents in the oil & gas industry. Fenofibrate is a white crystalline solid that is soluble in water, ethanol, and diethyl ether. It has an odor similar to fresh butter when it is ground or dissolved in water.
Application Insights:
The global market is segmented by application into hospitals, pharmacies and retail pharmacies, and online pharmacies. Hospitals were the largest application segment in 2017 accounting for over 70% of the overall revenue share. The high share of this segment can be attributed to growing geriatric population base that is prone to cardiovascular diseases along with increasing number of hospital admissions due to various injuries caused due to lack of proper safety measures at home. This has resulted in a significant increase in demand for fibrate drugs within this sector over the past few years.
Pharmacies are expected to be fastest-growing application sector during forecast period owing to rising awareness about availability of these drugs without prescription as well as increased competition among pharmacists regarding dispensing rates which may boost growth prospects during future phases also. Increasing dispensing rates have led pharma-cists towards adopting new technologies such as automated medication systems which will further propel growth opportunities during future phases also likely fueling industry expansion on a positive note soon enough!.
Regional Analysis:
Europe dominated the global market in terms of revenue in 2017. In addition, presence of regulatory bodies for fibrates such as EMA and FDA is also one factor responsible for Europe’s dominance over other regions.
Asia Pacific is anticipated to be the fastest-growing regional market during the forecast period owing to rising geriatric population prone to cardiac disorders along with increasing prevalence rate of type 2 diabetes that result in high blood glucose levels which increases risk factors for heart diseases such as hypertension and atherosclerosis.
Growth Factors:
- Increasing prevalence of obesity and metabolic syndrome
- Rising geriatric population
- Growing demand for combination therapies
- Technological advancements in fibrate drugs development
- Increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibrate Drugs Market Research Report
By Type
Lofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil
By Application
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Teva Pharmaceutical Industries, Pfizer, Inc., Mylan N.V., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Sun Pharmaceutical Industries, Inc., Macleods Pharmaceuticals Limited, Aurobindo Pharma, Abbott
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Fibrate Drugs Market Report Segments:
The global Fibrate Drugs market is segmented on the basis of:
Types
Lofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva Pharmaceutical Industries
- Pfizer, Inc.
- Mylan N.V.
- Sanofi SA
- Novartis AG
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries, Inc.
- Macleods Pharmaceuticals Limited
- Aurobindo Pharma
- Abbott
Highlights of The Fibrate Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lofibrate
- Fenofibrates
- Fenofibric Acids
- Gemfibrozil
- By Application:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibrate Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fibrate drugs are medications that help to reduce the amount of fat in the body. They work by reducing the production of cholesterol and triglycerides in the liver.
Some of the key players operating in the fibrate drugs market are Teva Pharmaceutical Industries, Pfizer, Inc., Mylan N.V., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Sun Pharmaceutical Industries, Inc., Macleods Pharmaceuticals Limited, Aurobindo Pharma, Abbott.
The fibrate drugs market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fibrate Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fibrate Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fibrate Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fibrate Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fibrate Drugs Market Size & Forecast, 2018-2028
4.5.1 Fibrate Drugs Market Size and Y-o-Y Growth
4.5.2 Fibrate Drugs Market Absolute $ Opportunity
Chapter 5 Global Fibrate Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Fibrate Drugs Market Size Forecast by Type
5.2.1 Lofibrate
5.2.2 Fenofibrates
5.2.3 Fenofibric Acids
5.2.4 Gemfibrozil
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Fibrate Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Fibrate Drugs Market Size Forecast by Applications
6.2.1 Hospitals Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fibrate Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fibrate Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Fibrate Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Fibrate Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Fibrate Drugs Market Size Forecast by Type
9.6.1 Lofibrate
9.6.2 Fenofibrates
9.6.3 Fenofibric Acids
9.6.4 Gemfibrozil
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Fibrate Drugs Market Size Forecast by Applications
9.10.1 Hospitals Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Fibrate Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Fibrate Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Fibrate Drugs Market Size Forecast by Type
10.6.1 Lofibrate
10.6.2 Fenofibrates
10.6.3 Fenofibric Acids
10.6.4 Gemfibrozil
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Fibrate Drugs Market Size Forecast by Applications
10.10.1 Hospitals Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Fibrate Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Fibrate Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Fibrate Drugs Market Size Forecast by Type
11.6.1 Lofibrate
11.6.2 Fenofibrates
11.6.3 Fenofibric Acids
11.6.4 Gemfibrozil
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Fibrate Drugs Market Size Forecast by Applications
11.10.1 Hospitals Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Fibrate Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Fibrate Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Fibrate Drugs Market Size Forecast by Type
12.6.1 Lofibrate
12.6.2 Fenofibrates
12.6.3 Fenofibric Acids
12.6.4 Gemfibrozil
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Fibrate Drugs Market Size Forecast by Applications
12.10.1 Hospitals Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Fibrate Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Fibrate Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Fibrate Drugs Market Size Forecast by Type
13.6.1 Lofibrate
13.6.2 Fenofibrates
13.6.3 Fenofibric Acids
13.6.4 Gemfibrozil
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Fibrate Drugs Market Size Forecast by Applications
13.10.1 Hospitals Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fibrate Drugs Market: Competitive Dashboard
14.2 Global Fibrate Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva Pharmaceutical Industries
14.3.2 Pfizer, Inc.
14.3.3 Mylan N.V.
14.3.4 Sanofi SA
14.3.5 Novartis AG
14.3.6 GlaxoSmithKline plc
14.3.7 Sun Pharmaceutical Industries, Inc.
14.3.8 Macleods Pharmaceuticals Limited
14.3.9 Aurobindo Pharma
14.3.10 Abbott
